Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SR-related CTD-associated factor 4 (SCAF4) is a member of the serine/arginine-rich (SR) splicing regulator family[3][4]. It encodes a protein of 1,147 amino acids, comprising a conserved CTD-interacting domain (CID) and an RNA recognition motif (RRM)[4]. SCAF4 interacts with the C-terminal domain (CTD) of the largest subunit of RNA polymerase II, functions as an anti-terminator by suppressing the premature usage of alternative polyadenylation sites, and links transcription with pre-mRNA splicing[1][2][3][4]. Together with SCAF8, it coordinates mRNA elongation and termination processes, ensuring that full-length, correctly processed mRNA is generated[4][7]. Loss of SCAF4 function causes broad deregulation of gene expression, alternative splicing, and truncated protein products, leading to neurodevelopmental disease phenotypes, intellectual disability, epilepsy, and association with ALS risk via regulatory variants[1][4][5][6]. Alternative splicing and transcript regulation mediated by SCAF4 have large effects on cell phenotype and function, but it does not fit in the classic mold of receptor, enzyme, or transporter drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SR-related CTD-associated factor 4 (SCAF4).